

# Y Lynn Wang

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7550857/y-lynn-wang-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

79  
papers

3,069  
citations

31  
h-index

55  
g-index

79  
ext. papers

3,455  
ext. citations

6.5  
avg, IF

4.62  
L-index

#	Paper	IF	Citations
79	SHP1 Loss Augments DLBCL Cellular Response to Ibrutinib: A Candidate Predictive Biomarker. <i>Blood</i> , <b>2021</b> , 138, 3490-3490	2.2	
78	Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2. <i>Blood Advances</i> , <b>2021</b> , 5, 185-197	7.8	1
77	Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 39	7	4
76	Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia. <i>Journal of Molecular Diagnostics</i> , <b>2020</b> , 22, 1114-1125	5.1	8
75	Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells. <i>Molecular Cancer Research</i> , <b>2019</b> , 17, 1365-1377	6.6	6
74	Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 1174-1184	12.9	14
73	System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 522-532	5.1	5
72	MYD88 Mutations and Sensitivity to Ibrutinib Therapy. <i>Journal of Molecular Diagnostics</i> , <b>2018</b> , 20, 264-266	5.1	5
71	XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IB. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2564-2574	6.1	24
70	Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. <i>Blood Advances</i> , <b>2018</b> , 2, 2039-2051	7.8	31
69	HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. <i>Oncogene</i> , <b>2017</b> , 36, 3441-3449	9.2	16
68	B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4212-4223	12.9	34
67	Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. <i>Journal of Molecular Diagnostics</i> , <b>2017</b> , 19, 43-56	5.1	69
66	Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. <i>Blood Advances</i> , <b>2017</b> , 1, 715-727	7.8	74
65	Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. <i>Oncotarget</i> , <b>2017</b> , 8, 12953-12967	3.3	26
64	Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL. <i>Oncotarget</i> , <b>2016</b> , 7, 68833-68841	3.3	47
63	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. <i>Oncotarget</i> , <b>2016</b> , 7, 4598-610	3.3	34

62	Clonal Evolution Pattern of Leukemia Progression and Richter Transformation in Ibrutinib-Relapsed CLL Patients. <i>Blood</i> , <b>2016</b> , 128, 3961-3961	2.2	
61	Genetic or CD40L-Mediated Loss of B $\pi$ s Associated with Resistance to the Dual SYK/JAK Inhibitor Cerdulatinib in DLBCL Cell Lines. <i>Blood</i> , <b>2016</b> , 128, 2768-2768	2.2	0
60	Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 445-56	4.5	65
59	Predicting Prognosis in Chronic Lymphocytic Leukemia in the Contemporary Era. <i>JAMA Oncology</i> , <b>2015</b> , 1, 965-74	13.4	39
58	Prognosis in Chronic Lymphocytic Leukemia-Reply. <i>JAMA Oncology</i> , <b>2015</b> , 1, 988-9	13.4	1
57	Amplicon Indel Hunter Is a Novel Bioinformatics Tool to Detect Large Somatic Insertion/Deletion Mutations in Amplicon-Based Next-Generation Sequencing Data. <i>Journal of Molecular Diagnostics</i> , <b>2015</b> , 17, 635-43	5.1	23
56	Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. <i>Leukemia</i> , <b>2015</b> , 29, 895-900	10.7	115
55	Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 43881-96	3.3	36
54	BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. <i>Leukemia</i> , <b>2014</b> , 28, 649-57	10.7	140
53	Ibrutinib resistance in chronic lymphocytic leukemia. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 2352-459.2		207
52	Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 849-61	4.5	68
51	Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation. <i>Journal of Molecular Diagnostics</i> , <b>2013</b> , 15, 556-64	5.1	20
50	Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , <b>2013</b> , 15, 733-44	5.1	34
49	Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q). <i>Human Pathology</i> , <b>2013</b> , 44, 346-56	3.7	10
48	Laboratory detection of JAK2V617F in human myeloproliferative neoplasms. <i>Methods in Molecular Biology</i> , <b>2013</b> , 999, 41-57	1.4	2
47	Strongyloides stercoralis infection presenting as an unusual cause of massive upper gastrointestinal bleeding in an immunosuppressed patient: a case report. <i>Tropical Doctor</i> , <b>2013</b> , 43, 46-8 <sup>0.9</sup>		12
46	Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. <i>Blood</i> , <b>2013</b> , 122, 2837-47	2.2	57
45	JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. <i>Haematologica</i> , <b>2013</b> , 98, e135-7	6.6	27

44	A Novel Mutation In Bruton Tyrosine Kinase Confers Acquired Resistance To Ibrutinib (PCI-32765) In CLL. <i>Blood</i> , <b>2013</b> , 122, 4914-4914	2.2	3
43	Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity In Both ABC and GCB Types Of Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2013</b> , 122, 1833-1833	2.2	
42	Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: heterogeneous morphology and cytological composition. <i>Modern Pathology</i> , <b>2012</b> , 25, 815-27	9.8	17
41	Certification in molecular pathology in the United States: an update from the Association for Molecular Pathology Training and Education Committee. <i>Journal of Molecular Diagnostics</i> , <b>2012</b> , 14, 541-549 <sup>1</sup>	5.1	2
40	Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. <i>Haematologica</i> , <b>2012</b> , 97, 538-42	6.6	26
39	BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity.. <i>Blood</i> , <b>2012</b> , 120, 2903-2903	2.2	
38	Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs. <i>Blood</i> , <b>2012</b> , 120, 5068-5068	2.2	
37	Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2011</b> , 11, 385-95	2	9
36	SYK inhibition and response prediction in diffuse large B-cell lymphoma. <i>Blood</i> , <b>2011</b> , 118, 6342-52	2.2	82
35	JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. <i>Leukemia Research</i> , <b>2011</b> , 35, 177-82	2.7	48
34	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. <i>Blood</i> , <b>2011</b> , 118, 1617-1617	2.2	
33	Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. <i>Blood</i> , <b>2010</b> , 116, e111-7	2.2	120
32	Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 587-99	12.9	47
31	Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. <i>American Journal of Pathology</i> , <b>2010</b> , 177, 1470-9	5.8	53
30	NK/T cell non-Hodgkin lymphoma in a HIV-positive patient. <i>Journal of Hematopathology</i> , <b>2010</b> , 3, 35-40	0.4	5
29	Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. <i>Leukemia</i> , <b>2009</b> , 23, 807-10	10.7	17
28	JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. <i>Nature Genetics</i> , <b>2009</b> , 41, 446-9	36.3	320
27	Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. <i>Gastroenterology</i> , <b>2009</b> , 136, 1242-50	13.3	117

26	Activity of SYK and PLC $\zeta$ Predict Apoptotic Response of Chronic Lymphocytic Leukemia Cells to SRC Tyrosine Kinase Inhibitor Dasatinib.. <i>Blood</i> , <b>2009</b> , 114, 1249-1249	2.2	
25	Decrease in JAK2V617F Allele Burden is Not a Prerequisite to Clinical Response in Patients with Polycythemia Vera (PV).. <i>Blood</i> , <b>2009</b> , 114, 1908-1908	2.2	1
24	Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. <i>Leukemia</i> , <b>2008</b> , 22, 1755-66	10.7	53
23	JAK2 Mutations are present in all cases of polycythemia vera. <i>Leukemia</i> , <b>2008</b> , 22, 1289	10.7	47
22	Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 654-60	4.5	40
21	Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. <i>Blood</i> , <b>2008</b> , 112, 3330-8	2.2	306
20	To Live or to Die: Prosurvival Activity of PPARgamma in Cancers. <i>PPAR Research</i> , <b>2008</b> , 2008, 209629	4.3	9
19	Targeting Early Events of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia: Suppressed Syk and PLC $\zeta$ Activities Predict Apoptotic Response of Leukemic Cells to Dasatinib. <i>Blood</i> , <b>2008</b> , 112, 5023-5023	2.2	
18	Evaluation of JAK2 in B and T cell neoplasms: identification of JAK2(V617F) mutation of undetermined significance (JMUS) in the bone marrow of three individuals. <i>Acta Haematologica</i> , <b>2007</b> , 118, 209-14	2.7	16
17	The proapoptotic factors Bax and Bak regulate T Cell proliferation through control of endoplasmic reticulum Ca(2+) homeostasis. <i>Immunity</i> , <b>2007</b> , 27, 268-80	32.3	86
16	Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism. <i>American Journal of Pathology</i> , <b>2007</b> , 170, 722-32	5.8	24
15	Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. <i>Journal of Molecular Diagnostics</i> , <b>2007</b> , 9, 272-6	5.1	54
14	JAK2 V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity.. <i>Blood</i> , <b>2007</b> , 110, 2530-2530	2.2	2
13	Quantitative Assessment of DNA Editing Enzymes in B-Cell Lymphomas.. <i>Blood</i> , <b>2007</b> , 110, 4687-4687	2.2	
12	Atypical Serum Immunofixation Pattern (ASIP) Development during Induction Therapy with BiRD for Newly Diagnosed Multiple Myeloma Correlates with a High Rate of Complete Remission.. <i>Blood</i> , <b>2007</b> , 110, 2737-2737	2.2	
11	Peroxisome proliferator-activated receptor gamma promotes lymphocyte survival through its actions on cellular metabolic activities. <i>Journal of Immunology</i> , <b>2006</b> , 177, 3737-45	5.3	31
10	beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia. <i>Journal of Molecular Diagnostics</i> , <b>2006</b> , 8, 385-9	5.1	16
9	Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts. <i>Journal of Molecular Diagnostics</i> , <b>2006</b> , 8, 231-9	5.1	28

8	Peroxisome Proliferator-Activated Receptor Gamma Promotes the Survival of Human T Lymphoma Cells through Its Regulation of Cellular Metabolism.. <i>Blood</i> , <b>2006</b> , 108, 2392-2392	2.2	
7	Detection of BCL2-IGH using single-round PCR assays. <i>Diagnostic Molecular Pathology</i> , <b>2005</b> , 14, 17-22		2
6	Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 31781-8	5.4	92
5	Chronic myelogenous leukemia: laboratory diagnosis and monitoring. <i>Genes Chromosomes and Cancer</i> , <b>2001</b> , 32, 97-111	5	43
4	Duplications and de novo deletions of the SMN1 gene demonstrated by fluorescence-based carrier testing for spinal muscular atrophy <b>1999</b> , 85, 463-469		43
3	An evaluation of the Factor V Leiden mutation in a cohort of African-American pregnant women. <i>Prenatal Diagnosis</i> , <b>1998</b> , 18, 315-317	3.2	3
2	Novel bcl-2 breakpoints in patients with follicular lymphoma. <i>Diagnostic Molecular Pathology</i> , <b>1998</b> , 7, 85-9		11
1	Regulation of self-tolerance by CD80/CD86 interactions. <i>Current Opinion in Immunology</i> , <b>1997</b> , 9, 858-62	7.8	42